Celsion to Present Two Posters with Data of GEN-1 in Ovarian Cancer at ASCO Meeting

Celsion to Present Two Posters with Data of GEN-1 in Ovarian Cancer at ASCO Meeting
Celsion Corporation will present two posters with key findings of its IL-12 gene-mediated immunotherapy, GEN-1, in ovarian cancer. The presentations will be made at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium in Orlando, Fla., Feb. 23-25. The first poster, titled “Phase I study and activity of formulated IL-12 plasmid administered intraperitoneally in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer,” will report clinical results from the OVATION Study. The Phase 1b dose-escalating clinical trial (NCT02480374) is testing GEN-1 administered in combination with standard neoadjuvant (pre-surgery) chemotherapy in patients newly diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer, who will undergo interval debulking surgery. The second poster, titled “Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer,” will report translational data from the OVATION Study and previous GEN-1 clinical trials. The OVATION Study has four dose groups meant to enroll three to six patients each, to identify a safe, tolerable, and effective dose of GEN-1. The first three groups enrolled three patients each and provided promising efficacy results. In January, Celsion revealed preliminary data, including the first three patients enrolled in the fourth group. In the first 12 patients dosed in total, which include patients from the fourth and final group, the combination therapy has shown promising efficacy signs, including 100% disease contr
Subscribe or to access all post and page content.